Retrospective comparison of the effects of filgrastim and pegfilgrastim on the pace of engraftment in auto-SCT patients

Bone Marrow Transplantation

Volumn 45, Issue 10, 2010, Pages 1522-1527

  Mathew, S ^a   Adel, N ^a   Rice, R D ^a   Panageas, K ^a   Duck, E T ^a   Comenzo, R L ^a,b   Kewalramani, T ^a,c   Nimer, S D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

auto SCT; engraftment; filgrastim; pegfilgrastim

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE PAIN; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; ENGRAFTMENT; ENGRAFTMENT SYNDROME; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION RISK; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; TREATMENT DURATION;

ADULT; AGED; ANTI-BACTERIAL AGENTS; COHORT STUDIES; FEMALE; FEVER; FILGRASTIM; HEALTH CARE COSTS; HEMATOLOGIC AGENTS; HEMATOLOGIC NEOPLASMS; HUMANS; INCIDENCE; LENGTH OF STAY; LEUKOPOIESIS; MALE; MIDDLE AGED; NEUTROPENIA; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 77957938720     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.373     Document Type: Article

References (21)

1. Afessa B, Peters SG. Major complications following hemato-poietic stem cell transplantation. Semin Respir Crit Care Med 2006; 27: 297-309.
2. Hamalainen S, Kuittinen T, Matinlauri I, Nousiainen T, Koivula I, Jantunen E. Severe sepsis in autologous stem cell transplant recipients: microbiological aetiology, risk factors and outcome. Scand J Infect Dis 2009; 41: 14-20.
3. Mossad SB, Longworth DL, Goormastic M, Serkey JM, Keys TF, Bolwell BJ. Early infectious complications in autologous bone marrow transplantation: a review of 219 patients. Bone Marrow Transplant 1996; 18: 265-271.
4. Richard S, Schuster MW. Stem cell transplantation and hemato-poietic growth factors. Curr Hematol Rep 2002; 1: 103-109.
5. Trivedi M, Martinez S, Corringham S, Medley K, Ball ED. Optimal use of G-CSF administration after hematopoietic SCT. Bone Marrow Transplant 2009; 43: 895-908.
6. Bhana N. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review. Curr Opin Oncol 2007; 19: 328-335.
7. Hornedo J, Sola C, Solano C, Lopez JJ, Alonso S, Lluch A et al. The role of granulocyte colony-stimulating factor (G-CSF) in the post-transplant period. Bone Marrow Trans-plant 2002; 29: 737-743.
8. Lee SM, Radford JA, Dobson L, Huq T, Ryder WD, Pettengell R et al. Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost. Br J Cancer 1998; 77: 1294-1299.
9. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 3187-3205.
10. Crawford J. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia. Semin Oncol 2003; 30(4 Suppl 13): 24-30.
11. Molineux G. Pegfilgrastim: using pegylation technology to improve neutropenia ssupport in cancer patients. Anticancer Drugs 2003; 14: 259-264.
12. Yowell SL, Blackwell S. Novel effects with polyethylene glycol modified pharmaceuticals. Cancer Treat Rev 2002; 28(Suppl A): 3-6.
13. Martino M, Pratico G, Messina G, Irrera G, Massara E, Console G et al. Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients. Eur J Haematol 2006; 77: 410-415.
14. Staber PB, Holub R, Linkesch W, Schmidt H, Neumeister P. Fixed-dose single administration of Pegfilgrastim vs daily Filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplant-ation. Bone Marrow Transplant 2005; 35: 889-893.
15. Jagasia MH, Greer JP, Morgan DS, Mineishi S, Kassim AA, Ruffner KL et al. Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study. Bone Marrow Transplant 2005; 35: 1165-1169. (Pubitemid 40895172)
16. Vanstraelen G, Frere P, Ngirabacu MC, Willems E, Fillet G, Beguin Y. Pegfilgrastim compared with Filgrastim after auto-logous hematopoietic peripheral blood stem cell transplantation. Exp Hematol 2006; 34: 382-388.
17. Porrata LF, Gertz MA, Inwards DJ, Litzow MR, Lacy MQ, Tefferi A et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplant-ation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001; 98: 579-585.
18. Yoong Y, Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Litzow MR et al. The effect of absolute lymphocyte count recovery kinetics on survival after autologous stem cell transplantation for non-Hodgkin's lymphoma. Leuk Lymphoma 2005; 46: 1287-1294.
19. Hiwase DK, Hiwase S, Bailey M, Bollard G, Schwarer AP. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2008; 14: 116-124.
20. Ballestrero A, Boy D, Gonella R, Miglino M, Clavio M, Barbero V et al. Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas. Ann Hematol 2008; 87: 49-55.
21. AMCP Guide to Pharmaceutical Payment Methods. Update (Version 2.0). J Manag Care Pharm 2009; 15(Suppl A): S3-S57 (quiz S58-S61).